405 Heron Drive Suite 200
Swedesboro, NJ 08085
Ph 800.331.8272
www.wedgewoodpetrx.com
Questions?
Call 1-877-357-9661

Cyclosporine for Veterinary Use

Veterinary: Order Online Now
Pet Owners: Pick Up and Fill a New Prescription

by Renee Kaswan, DVM, MS, Diplomate

ACVO


Overview

Therapeutic Class
Immunosuppressant

Species
Dogs and horses

May Be Prescribed by Vets for:
Dogs: keratoconjunctivitis sicca (KCS), Pannus (chronic superficial keratitis), Atopic blepharoconjunctivitis
Horses: Immune-mediated Keratouveitis.

Search for Available Dosage Forms 

Basic Information

Cyclosporine, also called cyclosporin A (CsA), was the first discovered and is the only commercially available drug in the cyclosporin category of immunosuppressive drugs.

Ask your vet these questions about compounded medications.

Cyclosporine is non-cytotoxic. It inhibits T-helper cell activity and shifts the regulation of the immune response towards immune tolerance. Since T-cells orchestrate most chronic immune responses, cyclosporine has broad anti-inflammatory effects. Its original indication was to prevent rejection in organ transplantation patients; its systemic indications currently include many autoimmune disorders.

The first commercial ophthalmic cyclosporine was Optimmune®, a 0.2% cyclosporine ointment made by Schering Plough Animal Health. Optimmune® was approved in 1995 in the Unites States to treat canine KCS and approved in Europe for KCS and pannus. Compounded ophthalmic cyclosporine drops have been used commonly in 1.0-2.0% concentrations in corn oil when Optimmune® was either commercially unavailable or owners were physically unable to apply an ointment. An aqueous suspension of 0.05% cyclosporine (Restasis®) was developed by Allergan Pharmaceuticals for treatment of KCS in human patients.

Lacrimogenic Effects

Topical cyclosporine has several beneficial effects in dry-eye patients. One of these effects is to directly increase secretion of physiologic tears. Physiologic tears (as opposed to artificial tears) contain growth factors to regulate corneal cell turnover and healing, lysozyme and antibodies for infection control and numerous nutritional elements required for the health of the avascular cornea. Topical CsA appears to facilitate lymphocytic apoptosis and suppress epithelial cell apoptosis, allowing regeneration of lacrimal gland tissue in dogs with KCS. Cyclosporine also restores conjunctival goblet cell mucin production. Topical CsA is an effective therapy for aqueous deficiency and for mucin deficiency dry-eye disorders in dogs.

Approximately 80% of dogs with KCS will increase tearing when treated with topical CsA. A major determinant in the success or failure of the individual KCS patient appears to be the stage of KCS at which CsA treatment is initiated. The lacrimal glands in KCS become progressively atrophied over the course of the disease. Dogs with a Schirmer Tear Test (STT) of 0 mm/min often have complete atrophy of the lacrimal glands and cannot respond to CsA; early treatment of KCS is therefore advocated. Dogs with congenital aplasia of the lacrimal glands and dogs with neurologic etiologies of KCS also are unlikely to increase tearing with CsA. However, even in dogs where lacrimation cannot be restored with CsA, the anti-inflammatory effects on the cornea and conjunctiva and regulating mucus production can be beneficial. The majority of KCS dogs require lifelong CsA-treatment. Interruptions in therapy lead to relapse of KCS.

Ocular-Surface Inflammatory Disorders

Topical CsA represents an important therapeutic addition for several autoimmune and immune mediated disorders of the ocular surface that previously were responsive only to corticosteroids. Dogs that receive chronic topical corticosteroids are in jeopardy of incurring a minor corneal abrasion, which under the influence of corticosteroids and collagenase activation may progress to a melting stromal ulcer. Cyclosporine does not activate collagenase, hence it is much safer for chronic use than corticosteroids, particularly in exophthalmic breeds susceptible to ocular injury.
Cyclosporine does not penetrate well into the inner eye and it is therefore seldom used to treat anterior uveitis. It reaches high concentrations in the cornea, conjunctiva, sclera and lids, where it is useful for suppressing chronic immune mediated disease. In treating chronic superficial keratitis (pannus), nictitans plasmacytic conjunctivitis and pigmentary keratitis, topical cyclosporine is effective whether used with topical corticosteroids or in place of corticosteroids. Anecdotal evidence suggests it also is useful to treat nodular scleritis, diffuse scleritis, follicular conjunctivitis and atopic blepharoconjunctivitis.

Adverse Effects and Precautions

  • Suppression of systemic lymphoblastogenesis has been reported in small dogs treated with 2% topical cyclosporine, but not with 0.2% (Optimmune®), suggesting that lower concentrations are advisable, particularly in small animals.
  • Ocular irritation reactions, including conjunctival hyperemia, periocular alopecia and blepharitis are common when topical
  • Cyclosporine is made from oral cyclosporine (Sandimmune®) but rarely are seen with Optimmune. Ingredients in the oral solution such as alcohol and surfactants as well as higher concentrations of CsA contribute to the irritation response. Cats have a lower tolerance to this ocular irritation than do dogs.
  • Experimentally, CsA-induced exacerbations of ocular herpes in cats occurred when used without concurrent virostatic agents.
  • Unlike corticosteroids, cyclosporine does not induce collagenase and is therefore not contraindicated in the presence of corneal ulcers.
  • Epiphora is an anticipated side effect of CsA in non dry-eye patients.
  • The bioavailability of CsA is affected by the oil in which it is dissolved. Corn oil and castor oil are desirable vehicles; mineral oil is particularly undesirable. Cyclosporine is an extremely stable molecule, however stability of the ophthalmic preparation is limited by solubility, oxidation of the vehicle and sterility.
Recommended frequency is usually twice daily and can be adjusted more or less frequently to effect. For KCS, ophthalmic cyclosporine usually needs to be continued lifelong. For transient ocular surface disorders it may be used periodically as needed.
 
 
About the Author

Dr. Renee Kaswan is a Diplomate in the College of Veterinary Ophthalmologists and former professor of ophthalmology at the University of Georgia College of Veterinary Medicine, where she taught for 17 years.

She devotes her career to investigating the causes of KCS in man and dog, and developing cyclosporine ophthalmic as the first truly therapeutic agent to treat this common disease.

Renee is internationally distinguished as the 'Queen of Dog tears' and aspires to similar recognition in human ophthalmology with the eventual approval of Restasis.


Though cyclosporine is often used in veterinary ophthalmology, one of its primary indications in veterinary health is for use as an immunosuppressant for immune-mediated diseases. A recent article in Veterinary Practice News highlights the efficacy of the oral capsules when treating atopic dogs, comparing it favorably to other commonly used treatment options. To read the published article, click here.

The information contained on this site is general in nature and is intended for use as an informational aid. It does not cover all possible uses, actions, precautions, side effects, or interactions of the products shown, nor is the information intended as medical advice or diagnosis for individual health problems or for making an evaluation as to the risks and benefits of using a particular product. You should consult your doctor about diagnosis and treatment of any health problems. Information and statements have not been evaluated by the Food and Drug Administration ("FDA"), nor has the FDA approved the products to diagnose, cure or prevent disease.

Wedgewood Pharmacy compounded veterinary preparations are not intended for use in food and food-producing animals.